Physicists have found a simple and effective way to skip over an energy level in a three-state system, potentially leading to ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

While Trump’s executive order provides substantial power to Elon Musk’s DOGE effort, it’s not specifically targeted to health ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in ...

Jean Folger has 15+ years of experience as a financial writer covering real estate, investing, active trading, the economy, and retirement planning. She is the co-founder of PowerZone Trading, a ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating ...

These cells coordinate bodily functions and movement quickly, often without intentional thought. They also can be affected differently by health conditions. Talk with your healthcare provider if you ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday. David Risinger has given his Buy rating due to a combination of factors ...

Vertex has built an empire in cystic fibrosis (CF) treatment, recently crowning its dominance with Alyftrek's approval last month. This latest CF drug adds even more firepower to a franchise ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

Under the terms of the chapter 11 plan confirmed by the U.S. Bankruptcy Court for the Southern District of Texas (the “Plan”), Vertex exited bankruptcy with a commitment of up to $100 million ...